A multivariable prediction model combining 18F-PSMA PET/CT and mpMRI for clinically significant prostate cancer: development and validation - Scorecard - MDSpire
Advertisement
A multivariable prediction model combining 18F-PSMA PET/CT and mpMRI for clinically significant prostate cancer: development and validation
Clinical Scorecard: Development and Validation of a Multivariable Model Integrating 18F-PSMA PET/CT and mpMRI for Predicting Clinically Significant Prostate Cancer
At a Glance
Category
Detail
Condition
Clinically Significant Prostate Cancer (csPCa)
Key Mechanisms
Integration of clinical parameters, mpMRI findings, and 18F-PSMA PET/CT data.
Target Population
Male patients aged ≥18 years with suspected prostate cancer.
Care Setting
Peking University First Hospital.
Key Highlights
Model developed using 1305 patients with suspected prostate cancer.
Final model includes PRIMARY score, PI-RADS score, and PSAD.
Training AUC of 0.916 with high sensitivity (96.0%) at recommended cutoff.
Guideline-Based Recommendations
Diagnosis
Use mpMRI and 18F-PSMA PET/CT for risk stratification in suspected prostate cancer.
Management
Consider biopsy for patients with csPCa defined as Gleason Grade Group ≥2.
Monitoring & Follow-up
Monitor PSA levels and imaging findings for risk assessment.
Risks
Avoid unnecessary interventions for low-risk disease.
Patient & Prescribing Data
Men with suspected prostate cancer undergoing biopsy.
Integration of imaging modalities improves diagnostic specificity.
Clinical Best Practices
Utilize the PI-RADS framework for lesion assessment.
Employ PSA density (PSAD) to enhance diagnostic accuracy.
